Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5965
    +0.0015 (+0.26%)
     
  • NZD/EUR

    0.5551
    +0.0010 (+0.19%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.86
    +0.29 (+0.35%)
     
  • GOLD

    2,358.70
    +16.20 (+0.69%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,115.93
    +37.07 (+0.46%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,030.96
    +113.68 (+0.63%)
     
  • Hang Seng

    17,675.82
    +391.28 (+2.26%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.2220
    +0.7260 (+0.78%)
     

Teva Presented New Data on Fremanezumab: What You Should Know

Teva Presented New Data on Fremanezumab: What You Should Know

During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.